Market Place
Sourcing Support
IECURE Earns FDA RMAT for ECUR-506 in Neonatal OTC Deficiency
07 Jan 2026 //
BUSINESSWIRE
iECURE to Present ECUR-506 Data in OTC Deficiency Trials
02 Oct 2025 //
BUSINESSWIRE
iECURE to Present Initial OTC-HOPE Clinical Data of ECUR-506
25 Aug 2025 //
BUSINESSWIRE
iECURE to Present OTC-HOPE Data of ECUR-506 at Medical Meeting
06 May 2025 //
BUSINESSWIRE
iECURE Gets FDA Fast Track For OTC Deficiency Therapy
07 May 2024 //
BUSINESSWIRE
iECURE Announces FDA Clearance of NDA for ECUR-506 to Initiate Trial
04 Apr 2024 //
BUSINESSWIRE
iECURE Secures Approval to Expand the OTC-HOPE Study of ECUR-506
06 Mar 2024 //
BUSINESSWIRE
iECURE Secures Clearance from TGA for Trial Application for ECUR-506
13 Dec 2023 //
BUSINESSWIRE
iECURE Appoints Gabriel M. Cohn, M.D., as Chief Medical Officer
16 Mar 2023 //
BUSINESSWIRE
iECURE gets fresh $65M to push pediatric liver disease gene therapy into clinic
30 Nov 2022 //
ENDPTS
Preclinical Data from iECURE’s GTP-506 shows Potential for OTC Deficiency
19 Oct 2022 //
BUSINESSWIRE
iECURE Receives FDA Orphan Drug Designation for GTP-506
06 Sep 2022 //
BUSINESSWIRE
iECURE Receives FDA Rare Pediatric Disease Designation for GTP-506
23 Aug 2022 //
BUSINESSWIRE
iECURE Enters Agreement with Center for Breakthrough Medicines
27 May 2022 //
CONTRACTPHARMA
Precision Bio Reports Q3 2021 Financial Results, Provides Business Update
10 Nov 2021 //
BUSINESSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.